JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Microbot Medical Inc

Slēgts

2.88 9.92

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.65

Max

2.89

Galvenie mērījumi

By Trading Economics

Ienākumi

791K

-2.6M

Darbinieki

20

EBITDA

-127K

-3.4M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+239.62% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 12. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

19M

111M

Iepriekšējā atvēršanas cena

-7.04

Iepriekšējā slēgšanas cena

2.88

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Microbot Medical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. aug. 23:11 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

2025. g. 5. aug. 22:45 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23%

2025. g. 5. aug. 22:39 UTC

Peļņas

Great-West Lifeco Logs Lower 2Q Profit

2025. g. 5. aug. 21:32 UTC

Peļņas

Coupang Posts Higher 2Q Sales Due to Customer Growth

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

NFL to Take 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

2025. g. 5. aug. 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

2025. g. 5. aug. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

2025. g. 5. aug. 23:19 UTC

Tirgus saruna

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

2025. g. 5. aug. 23:03 UTC

Tirgus saruna
Peļņas

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

2025. g. 5. aug. 22:22 UTC

Peļņas

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

2025. g. 5. aug. 22:21 UTC

Peļņas

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

2025. g. 5. aug. 22:20 UTC

Peļņas

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

2025. g. 5. aug. 22:18 UTC

Peļņas

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

2025. g. 5. aug. 22:15 UTC

Peļņas

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

2025. g. 5. aug. 21:58 UTC

Peļņas

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025. g. 5. aug. 21:30 UTC

Peļņas

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

2025. g. 5. aug. 21:26 UTC

Peļņas

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

2025. g. 5. aug. 21:23 UTC

Peļņas

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

2025. g. 5. aug. 21:17 UTC

Peļņas

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Salīdzinājums

Cenas izmaiņa

Microbot Medical Inc Prognoze

Cenas mērķis

By TipRanks

239.62% augšup

Prognoze 12 mēnešiem

Vidējais 9 USD  239.62%

Augstākais 9 USD

Zemākais 9 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Microbot Medical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

1

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.52 / 2.57Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Weak Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.